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Dysregulated mitochondrial function is associated with the pathology of a wide range
of diseases including renal disease and cancer. Thus, investigating regulators of
mitochondrial function is of particular interest. Previous work has shown that the von
Hippel-Lindau tumor suppressor protein (pVHL) regulates mitochondrial biogenesis and
respiratory chain function. pVHL is best known as an E3-ubiquitin ligase for the α-subunit
of the hypoxia inducible factor (HIF) family of dimeric transcription factors. In normoxia,
pVHL recognizes and binds hydroxylated HIF-α (HIF-1α and HIF-2α), targeting it for
ubiquitination and proteasomal degradation. In this way, HIF transcriptional activity is
tightly controlled at the level of HIF-α protein stability. At least 80% of clear cell renal
carcinomas exhibit inactivation of the VHL gene, which leads to HIF-α protein stabilization
and constitutive HIF activation. Constitutive HIF activation in renal carcinoma drives
tumor progression and metastasis. Reconstitution of wild-type VHL protein (pVHL) in
pVHL-defective renal carcinoma cells not only suppresses HIF activation and tumor
growth, but also enhances mitochondrial respiratory chain function via mechanisms that
are not fully elucidated. Here, we show that pVHL regulates mitochondrial function when
re-expressed in pVHL-defective 786O and RCC10 renal carcinoma cells distinct from
its regulation of HIF-α. Expression of CHCHD4, a key component of the disulphide
relay system (DRS) involved in mitochondrial protein import within the intermembrane
space (IMS) was elevated by pVHL re-expression alongside enhanced expression of
respiratory chain subunits of complex I (NDUFB10) and complex IV (mtCO-2 and COX
IV). These changes correlated with increased oxygen consumption rate (OCR) and
dynamic changes in glucose and glutamine metabolism. Knockdown of HIF-2α also
led to increased OCR, and elevated expression of CHCHD4, NDUFB10, and COXIV in
786O cells. Expression of pVHLmutant proteins (R200W, N78S, D126N, and S183L) that
constitutively stabilize HIF-α but differentially promote glycolytic metabolism, were also
Briston et al. VHL-Mediated Regulation of CHCHD4 and Mitochondria
found to differentially promote the pVHL-mediated mitochondrial phenotype. Parallel
changes in mitochondrial morphology and the mitochondrial network were observed.
Our study reveals a new role for pVHL in regulating CHCHD4 and mitochondrial function
in renal carcinoma cells.
Keywords: von Hippel-Lindau protein (pVHL), hypoxia inducible factor, mitochondria, bioenergetics, metabolism,
CHCHD4, respiratory chain
INTRODUCTION
Dysregulated mitochondrial function is associated with a broad
range of diseases including renal disease (1) and cancer (2).
Mitochondria are best known as the sites for cellular oxygen
consumption, generating chemical energy in the form of
adenosine triphosphate (ATP). In fact, mitochondria are not only
central to controllingmany cellularmetabolic pathways, but form
an intracellular network enabling them to move, interface with
other organelles (nucleus, endoplasmic reticulum, lysosome) and
signal to/from different cellular compartments and machinery
(3, 4). Thus, mitochondria are involved in regulating a broad
range of cellular activities.
Mitochondria communicate with the oxygen-sensing
machinery and are involved in regulating the cellular response to
hypoxia (5). The HIF (HIF-1 and HIF-2) dimeric transcription
factors are central to mediating hypoxia responses in cells.
Hypoxia and increased HIF activation occurs in most cancers,
leading to the upregulation of a range of genes involved in
diverse cellular processes including metabolism and cell survival
(6, 7). HIF comprises a tightly regulated HIF-α subunit (HIF-1α
and HIF-2α) and constitutively expressed HIF-1β subunit (7).
Under normal oxygen levels, HIF-α protein is continuously
synthesized and degraded. Targeting of HIF-α protein for
degradation is achieved through hydroxylation of conserved
proline residues, catalyzed by the oxygen-sensing dioxygenases,
prolyl hydroxylase domain (PHD) enzymes (7–9). Recognition of
the hydroxylated residues in HIF-α subunits is under the control
of the von Hippel-Lindau (pVHL) tumor suppressor protein
(10–12). pVHL forms the substrate recognition and catalytic
component of an E3-ligase complex which functions to poly-
ubiquitinate HIF-α subunits, targeting them for degradation by
the 26S proteasome (8, 11, 12).
Inactivation of VHL occurs in a large percentage of patients
with clear cell renal cell carcinomas (the most common form of
kidney cancer) (13). Loss of pVHL tumor suppressor function
promotes unopposed HIF-α stabilization and constitutive
HIF activation which is associated with tumor progression
(14). Re-constitution of wild-type pVHL or patient-derived
mutant pVHL proteins into pVHL-defective renal carcinoma
cells has proved a useful approach for investigating pVHL
function (15–19). Interestingly, re-expression of pVHL in renal
carcinoma cells increases the expression and activity of certain
respiratory chain subunits including complex IV (CIV) subunits,
mtCO-2 and COX IV (also known as COX4I1, COX4-1,
and COX IV-1) [(18, 19), Supplementary Table 1], increases
oxygen consumption rate (OCR) and mitochondrial DNA
(mtDNA) content (20, 21). Knockdown of HIF-1α or HIF-2α
in pVHL-deficient renal carcinoma cells has been shown to
enhance basal OCR, mtDNA content and increase COX IV
protein levels (20, 21). Collectively, these previous studies have
led to the idea that constitutive HIF activation in the context
of pVHL-defective renal carcinoma cells negatively regulates
mitochondrial function (20). However, increased expression
of mitochondrial respiratory chain subunits observed upon
pVHL re-expression in pVHL-defective renal carcinoma cells is
not HIF-α-dependent (21), suggesting that pVHL (positively)
regulates mitochondrial function independently of its HIF-
regulatory role through molecular mechanisms that have yet to
be fully elucidated.
Previously, we discovered that the coiled-coil helix coiled-coil
helix (CHCH) domain 4.1 (CHCHD4) mitochondrial import
protein is crucial for regulating intracellular oxygenation,
mitochondrial localization, and morphology (22, 23).
CHCHD4 [also known as MIA40 (24)] provides an import
and oxidoreductase-mediated protein folding function as a key
component of the disulphide relay system (DRS) within the
mitochondrial intermembrane space (IMS) (22–27). CHCHD4
substrates contain a twin-CXnC motif and include respiratory
chain subunits of complex I (CI) and CIV (22, 28–30).
Here, we further explore the role of pVHL in regulating
mitochondrial function, bioenergetics, and morphology.
We investigate effects on CHCHD4, metabolism and the
contribution of HIF-2α. We show that pVHL increases the
expression of CHCHD4, respiratory chain subunits known
to be CHCHD4 substrates (28, 29) and promotes changes
in mitochondrial morphology when re-expressed in pVHL-
defective renal carcinoma cells. Alongside, we show increased
OCR and dynamic changes in glucose and glutamine utilization.
Using a panel of pVHL mutants (R200W, N78S, S183L and
D126N) that are unable to degrade HIF-α, but promote
differential effects on glycolytic metabolism (31), we show that
these mutants also differentially affected the pVHL-mediated
mitochondrial phenotype. Collectively, our data provide
new molecular insight into the role of pVHL in regulating




Mitochondrial Protein Expression and
Increases Basal OCR
To explore the role of pVHL in the regulation of mitochondrial
function, we used matched 786O renal carcinoma cell lines stably
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expressing either an empty vector control (786O-EV) or re-
expressing wild-type pVHL (786O-VHL) (15). 786O parental
cells harbor a single nucleotide inactivating deletion in VHL,
and as a result express constitutively stabilized HIF-2α but
do not exhibit detectable HIF-1α protein (32) (Figure 1A).
Consistent with Hervouet et al. (21), we found that pVHL
re-expression enhanced the basal expression of respiratory
chain subunits of both nuclear and mitochondrial genetic
origin, including the CIV subunits mtCO-2 and COX IV
(Figure 1A). The expression of a number of distinct non-
electron transporting mitochondrial proteins, voltage-dependent
anion channel 1 (VDAC1), heat shock protein 60 (HSP60) and
ATP5B were not changed by pVHL re-expression (Figure 1A).
Evaluation of a panel of both nuclear (SDHA and COX4I1)
and mitochondrial encoded (ND6, cytochrome b and mtCO-
2) transcripts encoding mitochondrial proteins including those
major regulators of mitochondrial translation showed no
significant change (Figure 1B and Supplementary Figure 1),
indicating the observed increase in mitochondrial respiratory
subunit expression in the 786O-VHL cells was not due to changes
in mRNA.
CHCHD4 regulates the import of a range of mitochondrial
proteins including respiratory chain subunits of CI and CIV
(28–30). Bioinformatics analyses of the Cancer Genome
Atlas (TCGA-KIRC) data collection showed significantly
increased CHCHD4 expression in clear cell renal cell
carcinoma (ccRCC) designated as VHL non-mutated compared
with those designated as VHL mutated in the collection
(Figure 1C). Interestingly, we found that pVHL re-expression
enhanced CHCHD4 protein levels without significantly
affecting CHCHD4 mRNA in 786O cells (Figures 1D,E).
Furthermore, CHCHD4 knockdown reduced the levels of
respiratory chains subunits of CI (NDUFB10), complex
II (CII, SDHA), complex III (CII, UQCRC2), and CIV
(COX IV) in 786O cells (Figures 1F,G). Previously we
have shown that elevated CHCHD4 expression significantly
increases basal OCR and ATP levels in normoxia in
tumor cells expressing functional pVHL (22). Notably,
we found that prolonged exposure of 786O-EV cells to
hypoxia (1% O2, 72 h) reduced the growth of 786O-
VHL cells but had no significant effect on the growth of
786O-EV cells (Supplementary Figure 2B), indicating that
pVHL re-expression may lead to an increased reliance on
oxygen (and oxidative phosphorylation) for cell growth. In
relation to this, and consistent previous studies (20, 21),
we found that pVHL re-expression significantly increased
basal OCR, maximal respiratory capacity (Figures 2A–C
and Supplementary Figure 2) and ATP levels (Figure 2D).
Collectively, these data indicate that pVHL affects the expression
of CHCHD4 as well as the expression of other CHCHD4-
regulated respiratory chain subunits, basal OCR and ATP
levels.
Knockdown of HIF-α in renal carcinoma cells has been
shown to increase mitochondrial COX IV protein expression
(21) and basal OCR (20), implying a role for constitutive HIF-
α in negatively regulating mitochondrial respiration (20). In
agreement, we found that HIF-2α knockdown (HIF-2α KD)
significantly enhanced basal OCR and maximal respiratory
capacity in 786O cells (Figure 2E). As expected, in parallel,
we observed reduced expression of HIF-2α protein and HIF2A
mRNA levels, and a reduction in the levels of the HIF-2
target, GLUT-1 (Supplementary Figures 3A,B). Furthermore,
we found that stable HIF-2α knockdown led to elevated
CHCHD4, NDUFB10, and COX IV protein levels (Figure 2F).
These effects were more obvious with HIF-2α shRNA(1)
(Figures 2F,G) which gave better knockdown than HIF-2α
shRNA(2) (Supplementary Figure 3C). Alongside, we observed
significantly reduced expression of HIF2A and HIF-2 target
genes (VEGFa and CCND1) (Supplementary Figure 3D). These
data suggest that constitutive HIF-2α affects the expression
of CHCHD4 and mitochondrial respiratory chain subunits
NDUFB10 and COX IV in (pVHL-defective) renal carcinoma
cells, and this is associated with HIF-2α-dependent regulation of
OCR.
pVHL Re-expression Promotes Dynamic
Changes in Glucose and Glutamine
Metabolism
Previous studies have reported that re-expressing pVHL in
RCC10 renal carcinoma cells results in changes in glycolytic
metabolism (31, 33). Here, we performed metabolomics
analysis of 786O-EV and 786O-VHL cells. Consistent with
the observed pVHL-mediated increase in respiratory chain
subunit expression and enhanced OCR (Figures 1, 2), we
found a significant decrease in intracellular glucose levels
alongside a corresponding significant increase in intracellular
glutamine levels in 786O-VHL cells compared with 786O-
EV cells (Figures 3A,C). However, we found no significant
change in glucose or glutamine uptake, which was measured
in parallel by analyzing the media from 786O-VHL and
786O-EV cells (Figures 3B,D). Collectively, these data indicate
that pVHL re-expression leads to a change in glucose and
glutamine utilization consistent with increased respiratory
drive.
Culturing tumor cells in glucose-free (galactose-containing)
media forces them to utilize the respiratory chain and produce
ATP via oxidative phosphorylation (34). Thus to evaluate
the contribution of HIF-2α to respiration in the presence
and absence of glucose, we measured basal OCR in 786O
cells in the context of HIF-2α knockdown (Figure 3E). As
anticipated, shifting cells to glucose-free (galactose-containing)
media significantly increased basal OCR (Figure 3E), and
was observed for both control and HIF-2α knockdown
cells (Figure 3E). Notably, this effect on basal OCR was
more significant for HIF-2α knockdown cells than control
cells (Figure 3E). Moreover, compared to control cells
for each condition, HIF-2α knockdown caused a similar
increase in basal OCR in both glucose and glucose-free
(galactose-containing) media, indicating that HIF-2α loss
in (pVHL defective) renal carcinoma cells can promote
increased mitochondrial respiration under different metabolic
environments.
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FIGURE 1 | pVHL re-expression regulates mitochondrial protein expression. (A) Western blot analysis of mitochondrial protein expression in 786O-VHL (VHL, stably
re-expressing pVHL) cells and 786O-EV (EV, vector control) cells. α-tubulin and β-actin were used as load controls. Densitometric analysis of western blots show fold
change in mtCO-2 and COXIV protein levels normalized to β-actin and α-tubulin load controls respectively. (B) Graph shows relative expression of mRNA transcripts
(Continued)
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FIGURE 1 | (ND6, SDHA, cytochrome b, mtCO-2, and COX IV ) in 7860-VHL (VHL) and 786O-EV (EV) cells, measured using RT-qPCR. Data were analyzed using the
comparative Ct method (n = 4). (C) Boxplot of CHCHD4 expression in VHL mutated and VHL non-mutated ccRCC. TGCA-KIRC data was downloaded from
cBioportal. n = 534 patients were divided into VHL mutant (n = 202) and VHL non-mutant (n = 332) and analyzed for CHCHD4 expression in each group. Mean
expression VHL non-mutated = 235.8, VHL mutated= 212.0. Median values are shown for each group (black line), vertical size of the boxes are the interquartile range
(IQR), and whiskers represent 1.5 × IQR. Data were analyzed using a t-test with Welch’s correction p = 0.00034. (D) Western blots show CHCHD4 protein
expression in total (Load), cytoplasmic (Cyto), and mitochondrial (Mito) fractions from 786O-VHL (VHL) and 7860-EV (EV) cells. HCT116 cells transiently expressing
non-silencing control siRNA (NSC) or CHCHD4 siRNAs (CH), were used as controls for CHCHD4 protein expression (left two lanes). α-tubulin and VDAC1 were used
as cytoplasmic and mitochondrial protein markers respectively. (E) Graph shows relative expression of CHCHD4 mRNA expression in 7860-VHL and 786O-EV cells,
measured using RT-qPCR. Data analyzed using the comparative Ct method. Data are presented as mean ± S.E.M. n = 4 (not significant (n.s.) p > 0.05). (F) Western
blots show expression of mitochondrial proteins CHCHD4 and respiratory chain subunits NDUFB10 (CI), SDHA (CII), UQCRC2 (CIII), and COX IV (CIV) in 786O-EV
cells transiently expressing non-silencing control siRNA (NSC, 20 nM) or two independent CHCHD4 siRNAs (CH1 and CH2, 20 nM). α-tubulin and β-actin were used
as a load controls. (G) Relative expression of CHCHD4 mRNA in cells described in (A), measured using RT-qPCR. Data were analyzed using the comparative Ct
method. Data are presented as mean ± S.D. n = 3 (**p < 0.01).
pVHL Mutants Differentially Regulate
Mitochondrial Protein Expression, mtDNA
Copy Number and ATP Levels
To confirm the pVHL-dependent mitochondrial
effects we observed in 786O cells (Figures 1–3 and
Supplementary Figures 1–3), we used RCC10 cells (35).
RCC10 cells harbor an inactivating deletion in VHL (35),
but in contrast to the 786O cells, RCC10 cells constitutively
express both HIF-1α and HIF-2α proteins (Figure 4A). Pooled
RCC10 cell lines independently stably expressing either control
vector (pCMV), wild type pVHL (VHL), or a panel of mutant
forms of pVHL proteins (R200W, N78S, D126N, and S183L)
which are impaired in their ability to degrade HIF-α protein
(31, 36) (Figure 4A and Supplementary Figure 4A) were used.
The R200W mutation in VHL is associated with congenital
polycythemia (37), while its tumor suppressor activities are
considered to be close to wild type VHL (38). The N78S, D126N,
and S183L mutations in pVHL reduce its stability, and promote
differential effects on glycolytic metabolism (31). As anticipated,
these pVHL mutants were defective in blocking HIF activity and
unable to rescue constitutive expression of HIF targets (GLUT1,
BNIP3, and PHD3) (Figures 4A,B). However, whether these
pVHL mutations differentially regulate mitochondrial protein
expression and/or function is not known.
Consistent with our observations with 786O cells
(Figure 1), re-expression of pVHL in RCC10 cells led to
an increase in CHCHD4, and respiratory chain subunits
NDUFB10 (CI), SDHA (CII), UQCRC2 (CII), mtCO-2
(CIV), and COX IV (CIV) protein expression (Figure 4C and
Supplementary Figures 4B,C), while there was no change in
other mitochondrial proteins, such as VDAC1 and prohibitin-1
(PHB1) (Supplementary Figures 4B,C). Intriguingly, expression
of pVHL mutants had differential effects. Analysis of the R200W
mutant revealed a similar phenotype to re-expression of pVHL
(Figure 4C and Supplementary Figure 4). However, compared
to the R200Wmutant, the N78S mutant was less able to promote
an increase in the panel of mitochondrial proteins evaluated
(Figure 4C and Supplementary Figure 4), total cellular ATP
(Figure 4D), or mtDNA copy number (Figure 4E). Expression
of the N78S mutant in RCC10 cells has previously been shown
to exhibit markedly reduced glucose utilization and lactate
production compared to re-expression of wild type pVHL, while
two other mutants of pVHL, D126N and S183L were shown
to have intermediate effects which were more similar to wild
type pVHL (31). Like wild type pVHL, the D126N and S183L
mutants also promoted a significant increase in mitochondrial
proteins while the effect of the N78S mutant was less significant
(Supplementary Figure 4). Together these data indicate the
possibility that the pVHL-induced increase in mitochondrial
proteins, ATP and mtDNA copy number is mechanistically
separate from pVHL-mediated regulation HIF-α.
pVHL Mutants Differentially Regulate
Mitochondrial Morphology and the
Mitochondrial Network
To further explore the relationship between the pVHL and
mitochondria, 786O-VHL and 786O-EV cells were imaged using
confocal and electron microscopy (EM) to assess mitochondrial
morphology (Figures 5A,B). Clear differences in mitochondrial
morphology between the 786O-VHL and 786O-EV cells were
observed (Figures 5A,B). 786O-EV cells exhibited a more fused
and elongated mitochondrial phenotype compared to 786O-
VHL which appeared to have smaller and more fragmented
mitochondria (Figures 5A,B). Mitochondria appeared equally
dispersed throughout the cell in both 786O-EV and 786O-VHL
cells (Figure 5A). In agreement with the our images obtained
by live-cell confocal imaging (Figure 5A), ultrastructural analysis
by EM revealed that mitochondria appeared smaller and
more rounded in 786O-VHL cells, while mitochondria in
786O-EV cells appeared more elongated, thinner and more
tubular (Figure 5B). Quantification of mitochondrial length
from the EM images showed the average mitochondrial
length was significantly smaller in 786O-VHL cells (1.15µm)
compared to 786O-EV cells (1.54µm) (Figure 5C). Similar
mitochondrial morphology changes were observed in RCC10
cells stably expressing vector control (pCMV) and wild type VHL
(Figure 5D).
To further evaluate mitochondrial morphology, a panel
of RCC10 cells stably expressing vector control (pCMV),
wild type VHL (VHL), VHL mutants (R200W and N78S)
described in Figure 5 were fixed, and the mitochondrial network
examined using indirect immunofluorescence toward the ATP5B
subunit of the F1FO-ATPase. ATP5B protein expression was
unaffected by pVHL status (Figure 1A). Confocal imaging
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FIGURE 2 | pVHL re-expression or HIF-2α knockdown increases basal OCR. (A,B) Graphs shows routine (basal) OCR (A) and maximal respiratory capacity (B) in
786O-VHL (VHL) and 786O-EV (EV) cells. OCR (pmol.s−1) was corrected for cell number (per 106 cells) and non-mitochondrial respiration (n = 4). (C) Graph shows
respiratory flux ratios (R/E, routine control ratio; L/E, leak control ration; R-L/E, net-routine control ratio) calculated from OCR data described in (A) (n = 4). (D) Graph
(Continued)
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FIGURE 2 | shows luminescence (RLU) as a measure of total cellular ATP content in 786O-VHL (VHL) and 786O-EV (EV) cells, normalized to cell number (n = 3). (E)
Graph show routine (basal) OCR and maximal respiratory capacity in 786O-EV cells transiently expressing a non-silencing control siRNA (Ctrl) or HIF-2α siRNA (HIF-2α
KD). Data are presented as mean ± S.D. n = 4 (*p < 0.05) and (**p < 0.01). (F) Western blots show HIF-2α, COXIV and CHCHD4 protein levels in two independent
786O cell pools (i and ii) stably transduced with increasing amounts of control shRNA and two independent HIF-2α shRNAs(1) and (2). Data are representative of three
independent experiments. (G) Graphs show relative levels of CHCHD4, NDUFB10 and COX IV protein from densitometric analysis of western data from experiments
described in (F). Values were normalized to the load. Data are presented as mean ± S.D. (n.s. p > 0.05, *p < 0.05, ***p < 0.001, and ****p < 0.0001).
confirmed a similar change in mitochondrial morphology
to 786O cells upon re-expression of pVHL (Figures 5A,D,
6A and Supplementary Figure 5A). Images were analyzed
using the mitochondrial network analysis (MiNA) macro
tool (39) (Figures 6B–E and Supplementary Figure 5A).
RCC10 cells expressing the R200W mutant exhibited a
similar mitochondrial morphology to cells re-expressing
wild type pVHL (Figure 6), as they appeared fragmented
and less tubular compared to the control (pCMV) cells
(Figure 6A and Supplementary Figure 5A). We observed
a larger mitochondrial footprint in wild type pVHL and
R200W mutant cells compared to pCMV control cells as
there was significantly more area covered by mitochondrial
structures (Figure 6E). In contrast, RCC10 cells expressing the
N78S mutant exhibited a mitochondrial morphology similar
to the control (pCMV) cells (Figure 6), as they displayed
a more elongated mitochondrial appearance compared to
those re-expressing wild type pVHL (Figure 6). A similar
trend in results were obtained using live cell imaging of
the panel of RCC10 cells stained with the mitochondrial
dyes MitoTracker red (Supplementary Figures 5B–E) and
MitoView green (Supplementary Figure 5F), however
the mitochondrial network analysis was not statistically
significant (Supplementary Figure 5). Finally, consistent
with a previous study (18), and other settings (40), we
found no change in the expression of major regulators of
mitochondrial biogenesis including PGC-1α, PGC-1β , NRF-1,
NRF-2 (Supplementary Figures 6A–D), while mtDNA copy
number (Figure 4E and Supplementary Figure 6E) and TFAM
expression (Supplementary Figures 6F,G) was increased upon
pVHL re-expression. Taken together, these data indicate that
pVHL regulated mitochondrial morphology correlates with
changes in mitochondrial protein expression.
DISCUSSION
It is clear from previous studies that pVHL regulates
mitochondrial function in renal carcinoma (see
Supplementary Table 1). The negative regulation of the
HIF-α subunits by pVHL has understandably been the
focus of most attention and study, however other HIF-
independent functions of pVHL exist (41). Here, we show that
pVHL regulates mitochondrial protein expression, mtDNA
copy number, respiration and mitochondrial morphology
(Figure 6F).
Most strikingly, we found that expression of themitochondrial
DRS protein CHCHD4 (22, 23, 29) was affected by pVHL
status. CHCHD4 controls the import of a range of mitochondrial
proteins into the IMS (28), and as an oxidoreductase and key
component of the DRS, CHCHD4 along with ERV1/GFER
introduces disulphide bonds into imported substrates (29).
Previously, we have shown that elevated CHCHD4 expression
increases basal OCR, controls intracellular oxygenation and
regulates the mitochondrial network (22, 23). Here, pVHL re-
expression led to increased levels of a range of respiratory chain
subunits from CI-CIV including known CHCHD4 substrates
[e.g., the CI subunit, NDUFB10 (30)]. Thus, pVHL affects
CHCHD4 and mitochondrial function.
Reprogramming of glucose and glutamine metabolism occurs
in renal carcinoma (42). Loss of pVHL function causes HIF-
mediated enhanced glycolysis and inhibition of mitochondrial
function in renal carcinoma cells (20, 43). We found that
knockdown of HIF-2α in 786O cells caused elevated CHCHD4
and respiratory chain subunit expression and led to increased
basal OCR, suggesting the possibility that HIF-dependent
inhibition of mitochondrial function in pVHL mutated renal
carcinoma involves CHCHD4. Small molecule inhibitors that
target HIF show promise therapeutically in renal carcinoma
(17, 44–46). Tumor cells rely on glycolysis and mitochondrial
oxidative phosphorylation to survive (47). Thus, mitochondrial
metabolism has become an increasingly attractive area for
investigation and therapeutic exploitation in cancer (48). Our
study suggests that blocking HIF-2α in (pVHL-defective) renal
carcinoma induces CHCHD4 and promotes a metabolic profile
that could be exploited therapeutically. Thus, investigating the
importance of CHCHD4 expression levels in renal carcinoma
progression in the context of HIF dysregulation will be of
particular interest. In fact our bioinformatics analysis using
the Cancer Genome Atlas data collection (TCGA-KIRC)
revealed that CHCHD4 expression was significantly lower
in ccRCC patients designated with mutant VHL compared
to those ccRCC patients designated with wild-type VHL
(Figure 1C).
Along with changes in CHCHD4 and respiratory chain
subunit expression, we found that pVHL re-expression
caused a marked shift in fuel utilization: increased glucose
and decreased glutamine utilization, consistent with the
enhanced mitochondrial respiration. Using a panel of
pVHL mutants N78S, D126N, and S183L that exhibit
reduced stability and dysregulation of HIF-α but promote
differential effects on glycolysis (31), we discovered that
the pVHL-dependent effects on CHCHD4, mitochondrial
protein expression and morphology directly correlated
with pVHL-dependent regulation of metabolism. Our
data suggest that pVHL can promote effects on CHCHD4
and mitochondrial function that are separable from its
role in regulating HIF-α. Our previous study suggests
that CHCHD4 controls intracellular oxygenation and the
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FIGURE 3 | pVHL re-expression promotes dynamic changes in glucose and glutamine metabolism. (A–D) Graphs show, (A) intracellular glucose levels (n = 8),
(B) glucose uptake from extracellular media (n = 8), (C) intracellular glutamine levels (n = 7), and (D) glutamine uptake from extracellular media (n = 7) in 786O-VHL
(VHL) and 786O-EV (EV) cells measured by magnetic resonance spectroscopy (MRS). n = 7–8. (E) Graph shows basal OCR in 786O-EV cells transiently expressing a
non-silencing control siRNA (Ctrl) or HIF-2α siRNA (HIF-2α KD) and cultured in glucose (Glu) or glucose–free (galactose, Gal) media. Data are presented as mean ±
S.D. (n.s. p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001).
mitochondrial function upstream of HIF in the context of
hypoxia (23). Future work determining the contribution
of CHCHD4 and the DRS to pVHL-mediated regulation
of mitochondrial protein expression, respiration, and
mitochondrial morphology in the presence and absence
of HIF-α will provide further mechanistic insight into the
role of CHCHD4 in controlling mitochondrial function and
metabolism.
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FIGURE 4 | pVHL mutants differentially regulate mitochondrial protein expression, mtDNA copy number and ATP levels. (A) Western blots show HIF-1α, HIF-2α,
GLUT-1, and BNIP3 protein levels in RCC10 cells expressing empty vector (pCMV), wild type pVHL (VHL), or pVHL mutants (R200W or N78S). α-tubulin and β-actin
were used as load controls. (B) Relative expression of PHD3 mRNA in RCC10 cells described in (A), measured using RT-qPCR. Data were analyzed using the
comparative Ct method. Data are presented as mean ± S.E.M. n = 3 (n.s. p > 0.05, *p < 0.05, and ***p < 0.001). (C) Western blots show expression of
mitochondrial proteins CHCHD4 and VDAC1, and respiratory chain subunits NDUFB10 (CI), SDHA (CII), UQCRC2 (CIII), COX IV (CIV) in RCC10 cells described in (A).
pVHL expression was assessed as a control for re-expression, and β-actin and α-tubulin were used as load controls. (D) Graph shows total cellular ATP content in
RCC10 cells expressing wild type pVHL (VHL) or pVHL mutants (R200W or N78S), normalized to cell number (n = 4). (E) Graph shows mtDNA copy number in
RCC10 cells expressing pVHL variants, calculated using the ratio of expression of mitochondrial ND1 gene to the single copy nuclear gene, β2M to by RT-qPCR. Data
in (D,E) are presented as mean ± S.D. n = 6 (n.s. p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001).
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FIGURE 5 | pVHL re-expression affects mitochondrial morphology and the mitochondrial network. (A) Confocal microscope images of 786O-EV and 786O-VHL cells
stained with MitoView Green (100 nM). Images were acquired with a Zeiss 510 META confocal laser scanning microscope using a 63× oil objective. Representative
images and higher magnified images (right panel) are shown. (B) EM images of fixed 786O-VHL and 786O-EV cells. N = nucleus. Representative images and higher
(Continued)
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FIGURE 5 | magnified images (right panel) are shown. (C) Graph shows mitochondrial length measured from the EM images of fixed 786O-VHL (VHL) and 786O-EV
(EV) cells described in (B). Mitochondrial length was measured from the most highly curved membrane through the central axis to the opposite periphery.
Measurements were calculated using Image J software (National Institute of Health, Maryland) after calibration of scale using the scale bar. Over 200 mitochondria
were scored from independent images of 10 cells (***p < 0.001). (D) Confocal microscope images of RCC10 cells empty vector (pCMV) and wild type pVHL (VHL)




All chemicals were purchased from Sigma Aldrich unless
otherwise specified. The following antibodies were used for
immunoblotting: anti-pVHL [BD Pharmagen (Ig32; 556347;
1:1,000)], anti-α-tubulin (Sigma Aldrich; T6199; 1:5,000), anti-
CHCHD4 (Sigma Aldrich; HPA034688; 1:1,000), anti-HIF-2α
(Abcam; Ab199; 1:500), anti-ATP5B (Abcam; ab14730; 1:1,000),
anti-mtCO-2 (Abcam; ab110258; 1:1,000), anti-β-actin (Abcam;
6276; 1:5,000), anti-HSP60 [Cell Signaling Technology (CST);
#4870; 1:1,000], anti-VDAC1 (Abcam; ab15895;:1,000), anti-
COX IV (Abcam; ab14744; 1:1,000), anti-PHB1 (CST; #2426;
1:1,000), anti-anti-GLUT1 (Alpha Diagnostics; GT12-A; 1:1,000),
anti-DRP-1 (CST; #5391S; 1:1,000), anti-pDRP-1 (Ser637) (CST;
#4867S; 1:1,000), anti-HIF-1α (BD Biosciences; 610959; 1:1,000).
Horseradish peroxidase (HRP)-conjugated secondary antibodies
were purchased from Amersham and used at 1:5,000 dilution.
For immunocytochemistry anti-ATP5B (Abcam; ab14730) was
used at 1:500 dilution and Alexa Fluor 568 goat anti-mouse IgG
(Invitrogen; A-11031) was used at 1:5,000 dilution.
Cell Culture, siRNA Transfection, and
shRNA Lentiviral Transduction
The pVHL positive and negative 786O cells were kindly gifted
to us by William Kaelin Jr (Dana-Farber Cancer Institute,
Harvard Medical School), and have been described previously
(15). Stable pools of RCC10 cells expressing wild-type and
mutant VHL were supplemented with 0.5µM G418 (Sigma
Aldrich), and have been described previously (31). For shRNA
lentivirus production, HEK293T cells were used. All cells were
maintained in Dulbecco Modified Eagle Medium (DMEM;
Invitrogen), supplemented with 10% FCS, L-glutamine (2mM),
penicillin (100 U/ml) and streptomycin (100µg/ml) at standard
cell culture conditions (37◦C, 5% CO2 and 95% relative
humidity). Transient transfection was performed using a non-
silencing control siRNA duplex (Qiagen; 5′-AATTCTCCGAA
CGTGTCACGT-3′) and custom made siRNA to human HIF-
2α (Dharmacon; 5′-CCCGGATAGACTTATTGCCAA-3′) (17,
49). Transient transfection with siRNA duplexes (20 nM) were
performed using HiPerfectTM (Qiagen) or Lipofectamine 2000
(Invitrogen) transfection reagent according to manufacturer’s
instructions. Knockdown was confirmed by western blot analysis
and real-time quantitative polymerase chain reaction (RT-qPCR)
following 24 h siRNA incubation. For stable shRNA targeting
of HIF-2A, we used the shRNA expression vector, sGEP [a
gift from J. Zuber, IMP, Austria (50)]. The two independent
HIF-2A shRNA oligonucleotide sequences used for cloning are
listed in Supplementary Table 3, and were obtained from Sigma
Aldrich. For shRNA lentivirus production, HEK293T cells were
transfected with a mixture of the HIF-2A shRNA sGEP vector,
psPAX2 and pMD2.G using FuGENE 6 transfection reagent
(Promega E269A). The media containing the lentivirus was
collected 72 h post-transfection and filtered through a 0.45µM
PVDG sterile filter. 786O cells obtained from J. Massague
(MSKCC, New York) were transduced with the lentiviral
supernatant in the presence of 8µg/mL polybrene (Milipore)
and selected with 4µg/mL puromycin (Invivogen) for 48 h
post-transduction. Stable selected cell pools were expanded and
analyzed.
RNA Isolation and Complementary DNA
Synthesis
Total RNA was extracted from cells using RNeasy mini kit
with DNase digestion (Qiagen) as manufacturer’s instructions.
One microgram of total RNA was used for first strand
synthesis using the qScript First-Strand cDNA Synthesis
System (Quanta Biosciences). Complementary DNA (cDNA)
was synthesized using the G-Storm thermocycler as per
manufacturer’s instructions.
Real-Time Quantitative Polymerase Chain
Reaction (RT-qPCR)
Forward and reverse primers were used at a final concentration
of 0.5µM andMesa Blue SYBR green mix (Eurogentec) was used
as per manufacturer instruction. Data was analyzed using the
comparative cycle threshold (Ct) method using β-actin as the
internal control. Values from technical replicates were averaged
and analyzed using the equation below and as published (51):
Relative expression (2 −11Ct) = [(Ct gene of interest – Ct
internal control) sample A – (Ct gene of interest – Ct internal
control) sample B].
PCR primers were obtained from Sigma Aldrich and
sequences are outlined in Supplementary Table 2.
Mitochondrial Fractionation
Mitochondria were isolated using differential centrifugation.
Briefly, cells from confluent 15 cm plates were trypsinised
and washed in PBS. Cells were re-suspended in
homogenization buffer (250mM mannitol, 0.5mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)
pH 7.4 and 0.5mM ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA), 100x EDTA-free protease
inhibitor cocktail). Cells were homogenized with a glass-on-glass
Dounce homogenizer using 100 strokes of a tight fitting pestle.
A small volume of the total cell homogenate was removed and
stored (load fraction). The homogenate was centrifuged at 900
g for 10min to pellet nuclei and intact cells, the supernatant
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FIGURE 6 | pVHL mutants differentially regulate mitochondrial morphology and the mitochondrial network. (A) Confocal microscope images of RCC10 cells empty
vector (pCMV), wild type pVHL (VHL), or pVHL mutants (R200W or N78S). Cells were fixed and mitochondria were stained for ATP5B (red). Nuclei were stained with
DAPI (blue) and images were acquired with a Zeiss 510 META confocal laser scanning microscope using a 63× oil objective. Right panels show mitochondria (red) in
(Continued)
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FIGURE 6 | higher magnified images. (B–E) Graphs show analysis of mitochondria from ATP5B stained cells described in (A) using MiNA (39). Graphs show number
of mitochondria that are unbranched (B) and branched (C), mean number of branched mitochondria per network (D) and the mitochondrial footprint normalized to
pCMV control (E) for each cell line as indicated. n = 28 (pCMV, VHL), n = 13 (R200W), n = 14 (N78S). Data are presented as mean ± S.E.M. and analyzed using a
one-way ANOVA with Tukey’s post-hoc comparison. (n.s. p > 0.05, **p < 0.01, and ***p < 0.001). (F) pVHL-mediated regulation of CHCHD4 and mitochondrial
function. pVHL re-expression in VHL-defective renal carcinoma cells leads to increased expression of CHCHD4 and respiratory chain subunits (from CI to CIV),
increased respiration (OCR), ATP production, mtDNA copy number, changes in metabolism (glucose and glutamine), and changes in mitochondrial morphology (less
fused/elongated). pVHL mutants exhibit differential effects.
containing mitochondria was removed and this step was
repeated and supernatant again removed. Mitochondria were
sedimented following centrifugation at 9,000 g for 10min. The
supernatant was removed and stored (cytosolic fraction). The
crude mitochondrial pellet was washed in homogenization buffer
and centrifuged at 9,000 g for 10min. The pellet was lysed in 1%
NP40 lysis (mitochondrial fraction). All steps were performed
on ice and centrifugation was performed at 4◦C.
Measurement of Total Cellular ATP
Cells were counted and re-suspended in complete media. To
determine ATP concentration Cell-Titer Glo reagent (Promega)
was used as outlined in the manufacturer’s instructions.
Luminescence was quantified using a Tropix TR717 microplate
reader.
High-Resolution Respirometry
Cellular oxygen consumption rates were measured using
the Oxygraph 2K (O2K; Oroboros Instruments). Cells were
trypsinised and re-suspended in HEPES-buffered DMEM and
counted. Cells were added to each chamber and incubated at
37◦C under constant stirring (750 rpm). Cells were allowed to
reach routine baseline respiration before the addition of the first
compound. Two µg/ml oligomycin, 0.5µM increments FCCP,
0.5µM rotenone, and 2.5µM antimycin A were injected in
sequence and the rates of oxygen consumption assessed.
Determination of mtDNA Copy Number
Total DNA was isolated from cell pellets using QIAamp DNA
blood mini kit (Qiagen). Abundance of mitochondrial DNA
relative to nuclear genomic DNA was determined by qRT-PCR
using primers for ND1 (mitochondrial, forward 5′-TCCTCTCC
CGCTCTGCACCC-3′ and reverse 5′-GGCGGGCCACCAAGG
AGAAC-3′) and beta-2-microglobulin (β2M; nuclear, forward 5′-
GCCCCAACGTTGTAGGCCCC-3′ and reverse 5′- AGCTAAG
GTCGGGGCGGTGA-3′). Estimation of the number of copies of
the mitochondrial genome relative to nuclear genome was based
on the threshold cycle (Ct) as described previously (52).
Immunostaining
Cells were plated on glass coverslips (ø 13mm, VWR) and
incubated overnight. Cells were washed twice with PBS and fixed
using 4% paraformaldehyde in PBS for 15min. Cells were then
washed twice with PBS and permeabilized for 10min using 0.5%
Triton X in PBS before being blocked with IFF (1% BSA, 1%
FCS in PBS) for 1 h. Coverslips were incubated overnight with
primary antibody at 4◦C before being washed and incubated with
fluorophore conjugated secondary antibody for 1 h. Coverslips
were again washed twice with PBS and incubated in 1µg/ml
DAPI solution (Biotium) for 10min, washed and mounted using
Fluoromount G (Southern Biotech). DAPI was excited at 405 nm
and emitted fluorescence (peak 465 nm) collected using 435–
485 band pass filter and red fluorescence captured following
excitation at 543 nm and collected using a 560 nm long pass filter.
Images were acquired with a Zeiss 510 META confocal laser
scanning microscope using a 63× oil immersion objective.
Confocal Live-Cell Imaging
Cells were seeded on to glass coverslips (ø 22mm, VWR) and
Mitoview green (Biotium) used for mitochondrial imaging at a
concentration of 100 nM. Mitoview green was excited at 488 nm
and emitted fluorescence captured using a 505–530 band pass
filter. Images were acquired with a Zeiss 510META confocal laser
scanning microscope using a 63× oil immersion objective.
Analysis of Mitochondrial Network
Morphology
Fluorescently-labeled mitochondrial networks within cultured
cells were analyzed using the Mitochondrial Network Analysis
(MiNA) macro tool (39) in ImageJ. Pre-processing to enhance
image quality was uniformly performed across images using
the built-in contrast limited adaptive equalization, median
filtering, and top-hat filtering options. Regions of interest
containing single cells were selected for analysis and a
mitochondrial footprint for each cell per image was generated.
The mitochondrial footprint is the total area occupied by
mitochondrial signal (i.e., mitochondrial structures) separated
from the background, and is calculated by multiplying the
number of pixels containing signal in the binarized image (only
mitochondrial signal included) by the area of a pixel.
Electron Microscopy
Cells were seeded on to glass coverslips (ø 13mm, VWR), and
fixed with 2% paraformaldehyde and 1.5% glutaraldehyde in
0.1M cacodylate buffer. Samples were post fixed with 1% osmium
tetraoxide and 1.5% potassium ferrocyanine in 0.1M cacodylate
buffer. Samples were dehydrated in a graded ethanol-water series,
cleared in propylene oxide and infiltrated with agar-100 resin.
Ultra-thin sections were cut and collected on 300-mesh grids
and stained with lead citrate. Samples were viewed in a Joel
1010 transition electron microscope and images were acquired
using a Gatan Orius CDD camera. Mitochondrial length was
analyzed using ImageJ measure feature, calibrated using the scale
bar of each image. Analysis of up to 15–20 mitochondria from
10 cells per condition was performed. Statistical significance was
calculated using an unpaired two-tailed t-test.
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Metabolomics Analyses to Determine the
Levels of Intracellular Glucose and
Glutamine and Their Uptake From the
Culture Media
For the intracellular glucose and glutamine measurements, cells
were methanol fixed, and harvested by scraping, then phase
separated by the serial addition of chloroform andwater, followed
by centrifugation. Divalent ions were removed by the addition
then removal by centrifugation of Chelex 100. Cell extracts were
prepared for 1H-MRS by freeze drying, followed by resuspension
in D2O and 0.75% TSP (in D2O) at a 14:1 ratio. For the glucose
and glutamine uptake measurements, 1H-MRS were performed
on 500 µl of culture media samples (starting media that has
not been incubated with the cells and media samples that has
been collected just before cell harvest for extractions) with the
addition of 50 µl of D2O and 50 µl of 0.75% TSP. 1H-MR
spectra of the extracted andmedia samples were acquired at 25◦C
using a pulse-acquired MR sequence with water suppression (1D
NOESY presat sequence) in a broad-band-inverse NMR probe on
a Bruker 500 MHz NMR system.
Sulforhodamine B (SRB) Assay
Cells were plated in appropriate tissue culture vessels, and
allowed to adhere overnight prior to treatment. At the end of
incubation, media was removed and cells were fixed with 10%
trichloroacetic acid (TCA) for 30min. TCA was washed with
water, wells were allowed to air dry, and then an excess of 0.4%
(w/v) SRB in 1% acetic acid was used to stain fixed cells for
>10min. Excess SRBwas washed off with 1% acetic acid solution.
Bound SRB was resuspended in a suitable volume of 10mM Tris,
and absorbance of solutionmeasured at 570 nm. For proliferation
assays, cells were plated on “day−1” in triplicate in 12 well plates,
and cultured in maintenance DMEM overnight, after which
“day 0” plates fixed with TCA. For galactose conditions, glucose
media was replaced with glucose-free DMEM, supplemented
with 4.5 g/L galactose, 10% FCS, penicillin, streptomycin and L-
glutamine, and 1mM pyruvate. Cells were then incubated for
desired time points in either normoxia or hypoxia, followed by
SRB assay.
Experimental Design, Data Analysis, and
Statistical Procedures
Data are presented as mean ± standard deviation (S.D) or
standard error (S.E.M). Statistical analysis was performed using
an unpaired two-tailed t-test in GraphPad Prism version 7.02
for Windows (La Jolla, California, USA) or otherwise indicated
in figure legends. Statistical significance was determined using
P < 0.05.
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